All entries

Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing.

A fragment of Thymosin Beta-4. Drives cell migration and tissue repair, used for chronic soft-tissue stuff.

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

Alpha-MSH analog. Drives melanin production. Cleaner side effect profile than MT-2.

Copper-binding tripeptide. Supports collagen, wound healing, and hair follicles. Topical or sub-q.

Selective GH secretagogue. Bumps natural GH pulses without hitting cortisol or prolactin.

GHRH analog. Pairs with Ipamorelin to amplify natural GH pulses. The 'no-DAC' version stays short-acting on purpose.

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

Less selective alpha-MSH analog. Stronger pigmentation than MT-1, but also hits libido and brings rougher side effects.

Oral ghrelin mimetic. Bumps GH and IGF-1 without injections. Strong appetite stimulation is the trade-off.

Melanocortin agonist. FDA-approved as Vyleesi for female sexual dysfunction. Used off-label for libido in both sexes.

GHRH analog. FDA-approved for HIV-associated lipodystrophy. Used off-label for visceral fat reduction.

GHRH analog, the older sibling to Tesamorelin and CJC. Restores natural GH pulses, gentler profile.

Tetrapeptide derived from epithalamin. Studied for telomerase activation and circadian / pineal support. Limited human data.

Modified fragment of HGH (residues 176-191). Targets fat metabolism without the full GH side effect profile.

NNMT inhibitor. Targets the enzyme that drives metabolic stagnation in obesity. Early human and animal data.

Tripeptide fragment of alpha-MSH. Anti-inflammatory, used for gut conditions and skin inflammation.

Russian-origin synthetic peptide. Anxiolytic and cognitive support without the sedation profile of benzos.

Mitochondrial-derived peptide. Targets metabolic flexibility, insulin sensitivity, and exercise response.

Recombinant human growth hormone — the protein itself, not a peptide that nudges your body to make more. Highest legal-risk compound in this catalog.

Long-acting amylin agonist. Different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.

Boehringer Ingelheim dual agonist (GLP-1 + glucagon). Glucagon activation boosts metabolic rate, giving stronger fat-burn signal than GLP-1-only drugs.

Long-acting form of insulin-like growth factor 1. Used for muscle anabolism. Limited human safety data and a real side-effect profile — handle with discipline.

Most potent GH secretagogue. Stronger pulse than Ipamorelin but with cortisol and prolactin bumps. Short cycles only.

Delta Sleep-Inducing Peptide. A brain-origin peptide aimed at sleep architecture. Limited human data, mixed user reports.

The fat-loss tail of the HGH molecule, isolated and used alone. Goal: trigger lipolysis without GH's water retention or insulin impact.

Russian-origin tetrapeptide aimed at brain aging and circadian function. Limited human data — treat as experimental.

Immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery.

Russian-origin nootropic peptide. Alert/focus end of the spectrum. Pairs with Selank for a balanced cognitive stack.